Overview

Extension Study of Pegylated Somatropin to Treat Growth Retardation Caused by Endogenous Growth Hormone Deficiency in Children

Status:
Unknown status

Trial end date:
2021-09-01

Target enrollment:

Participant gender:

Summary

1. To further evaluate the safety and efficacy of PEG-Somatropin in the treatment of children with growth hormone deficiency for a relatively long period 2. To explore the factors influencing the efficacy of PEG-Somatropin and to establish the height prediction model based on Chinese children with short stature, and to provide the basis and guidance for standard and reasonable long-term clinical application of PEG-Somatropin.

Phase:

Phase 4

Details

Lead Sponsor:

GeneScience Pharmaceuticals Co., Ltd.

Treatments:

Hormones